40 minutes ago
Investigators explored the measurement properties of the Patient-Reported Outcomes Measurement Information System (PROMIS) among patients with chronic skin disease.
17 hours ago
The CRL notes that additional mechanistic and natural history data have not altered the previous review conclusions.
21 hours ago
The novel oral NMDA receptor antagonist, sigma-1 agonist, and aminoketone CYP2D6 inhibitor has indicated its efficacy and safety across 3 clinical trials.
22 hours ago
The FDA has issued a CRL for selective cortisol modulator relacorilant, citing a need for more evidence of effectiveness.
22 hours ago
The FDA has approved oral neurokinin-1 receptor antagonist tradipitant for the prevention of motion sickness, marking the first approval in decades.